27 completed, 9 not yet recruiting, 9 unknown, 8 recruiting. 18 Not applicable, 12 Phase 3, 8 Phase 2, 7 Phase 1, 6 Phase 4.
Follow T2DM (Type 2 Diabetes Mellitus): new trials by email Literature Review of T2DM (Type 2 Diabetes Mellitus) trials Research Report on T2DM (Type 2 Diabetes Mellitus)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin SYH2069 Injection (group 1), SYH2069 Injection (group 2), SYH2069 Injection (group 3) - T2DM (Type 2 Diabetes Mellitus) | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 240 | 2026-11-06 | 2026-09-01 |
| Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic Function DA-302168S - Obesity, Overweight, T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Not yet recruiting | Chendu DIAO Pharmaceutical Group CO., LTD. | 32 | 2026-10-22 | 2026-10-15 |
| Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release Tablets Chiglitazar/Metformin extended-release tablets under fasting conditions, Chiglitazar/Metformin extended-release tablets after a high-fat meal, multiple-dose of Chiglitazar/Metformin extended-release tablets - T2DM (Type 2 Diabetes Mellitus) | Phase 1 | Not yet recruiting | Chipscreen Biosciences, Ltd. | 28 | 2026-10-08 | 2026-04-06 |
| Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease pulsENDO treatment - T2DM (Type 2 Diabetes Mellitus), MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease | Not applicable | Recruiting | Chinese University of Hong Kong | 40 | 2026-09-01 | 2026-09-15 |
| Chiglitazar Added to SGLT-2 Inhibitors for Type 2 Diabetes SGLT-2 inhibitor and Chiglitazar, SGLT-2 inhibitor and Other Oral Antidiabetic Drugs (OADs) - T2DM (Type 2 Diabetes Mellitus) | Not yet recruiting | Chipscreen Biosciences, Ltd. | 3550 | 2026-07-18 | 2026-05-12 | |
| Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets Chiglitazar/Metformin extended-release fixed-dose combination tablet, dose 1, Chiglitazar tablet, dose 1, Metformin extended-release tablet, dose 1 - T2DM (Type 2 Diabetes Mellitus) | Not applicable | Completed | Chipscreen Biosciences, Ltd. | 64 | 2026-07-09 | 2026-09-23 |
| Anti-inflammatory Dietary Intervention in Patients With Type 2 Diabetes: A Randomized Controlled Trial Anti-inflammatory Dietary Intervention, Standard Diabetes Dietary Advice - T2DM (Type 2 Diabetes Mellitus) | Not applicable | Recruiting | Anhui Medical University | 88 | 2026-06-03 | 2026-06-18 |
| To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes Mellitus DWP16001, DWC202518, Placebo of DWP16001 - T2DM (Type 2 Diabetes Mellitus) | Phase 3 | Not yet recruiting | Daewoong Pharmaceutical Co. LTD. | 510 | 2026-06-01 | 2026-06-02 |
| Pilot Bioequivalence Study of Chiglitazar/Metformin Extended-Release Tablets treatment T (dose 1), treatment T (dose 2), treatment R (dose 1) - T2DM (Type 2 Diabetes Mellitus) | Not applicable | Completed | Chipscreen Biosciences, Ltd. | 24 | 2026-05-15 | 2026-09-23 |
| Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease Dulaglutide, SGLT2i, Finerenone - T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wannan Medical College | 468 | 2026-05-01 | 2026-04-22 |
| Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type 2 Diabetes Mellitus Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets - T2DM (Type 2 Diabetes Mellitus) | Not yet recruiting | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 300 | 2026-02-20 | 2026-02-27 | |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus ASC30 tablets, Placebo - T2DM (Type 2 Diabetes Mellitus) | Phase 2 | Completed | Ascletis Pharma (China) Co., Limited | 100 | 2026-01-22 | 2026-10-30 |
| A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus Chiglitazar Placebo, Chiglitazar, vitamin E - MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus) | Phase 2 | Recruiting | Shanghai Jiao Tong University School of Medicine | 300 | 2026-01-01 | 2026-06-03 |
| Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease ganagliflozin, Placebo - T2DM (Type 2 Diabetes Mellitus), CKD - Chronic Kidney Disease | Phase 4 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 1244 | 2025-11-30 | 2025-11-18 |
| Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine CGM-Augmented FIM, FIM only - Nutrition, Type 2 Diabetes | Not applicable | Active not recruiting | University of North Carolina, Chapel Hill | 60 | 2025-09-19 | 2026-08-17 |
| GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM semaglutide, Standard Treatment (Guideline-Based) - T2DM (Type 2 Diabetes Mellitus) | Phase 4 | Recruiting | Federico II University | 80 | 2025-09-08 | 2026-01-02 |
| Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D Fitbit and AI Chatbot, Routine Care - Type 2 Diabetes, Type 2 Diabetes Mellitus (T2DM) | Completed | University of Colorado, Denver | 35 | 2025-09-03 | 2026-08-19 | |
| Detecting Type 2 Diabetes From Voice Type 2 Diabetes, Diabetes (DM) | Completed | Thymia Limited | 7319 | 2025-09-01 | 2026-03-19 | |
| Group Emotion-Focused Behavioral Intervention for Diabetes Distress/A1c in T2D. Group Emotion Focused Behavioral Intervention (G-EFBI), Group - With Every Heartbeat is Life (G-WEHL) - T2DM (Type 2 Diabetes Mellitus) | Not applicable | Not yet recruiting | Ohio State University | 120 | 2025-09-01 | 2025-04-06 |
| Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control Metformin, Triple Therapy of Other Oral Antidiabetic Drugs, ganagliflozin - T2DM (Type 2 Diabetes Mellitus) | Phase 4 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 430 | 2025-03-29 | 2025-11-24 |
Showing 20 of 62. Sign in to see all of them.
Diabetes Mellitus, Type 2 (62) · Obesity (5) · Diabetes Mellitus (3) · Non-alcoholic Fatty Liver Disease (3) · Renal Insufficiency, Chronic (3) · Glucose Intolerance (2) · Overweight (2) · Albuminuria (1) · Atrial Fibrillation (1) · Body Weight (1) · Diabetic Nephropathies (1) · Dyslipidemias (1) · Endocrine System Diseases (1) · Fatty Liver (1) · Glucose Metabolism Disorders (1)
Nutritional and Metabolic Diseases (62) · Endocrine System Diseases (61) · Glucose Metabolism Disorders (61) · Metabolic Diseases (61) · Diabetes Mellitus (59) · Pathological Conditions, Signs and Symptoms (11) · Signs and Symptoms (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Nutrition Disorders (5) · Overnutrition (5) · Pathologic Processes (5) · Urogenital Diseases (5) · Urologic Diseases (5)
Enavogliflozin (6) · chiglitazar (4) · Metformin (3) · dapagliflozin (3) · Fish Oils (2) · Insulin (2) · 6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol (1) · Anastomosis, Roux-en-Y (1) · Bariatric Surgery (1) · Biliopancreatic Diversion (1) · Bread (1) · Ciprofloxacin (1) · Clinical Laboratory Techniques (1) · Dabigatran (1) · Edetic Acid (1)
Daewoong Pharmaceutical Co. LTD. (8) · Chipscreen Biosciences, Ltd. (4) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (2) · Oramed, Ltd. (2) · Shenzhen HighTide Biopharmaceutical Ltd. (2) · University of British Columbia (2) · AJU Pharm Co., Ltd. (1) · Al-Mustansiriyah University (1) · Anhui Medical University (1) · Ascletis Pharma (China) Co., Limited (1) · Beijing Hospital (1) · Besins Healthcare (1) · CSPC Ouyi Pharmaceutical Co., Ltd. (1) · Chendu DIAO Pharmaceutical Group CO., LTD. (1) · Chinese University of Hong Kong (1)
China (15) · United States (11) · South Korea (10) · Canada (4) · Italy (3) · India (2) · Japan (2) · Russia (2) · United Kingdom (2) · Australia (1) · Bahrain (1) · Brazil (1) · Egypt (1) · France (1) · Hong Kong (1)
Colin Dormuth, ScD (2) · Kui Liu, MD (2) · Anna Kahkoska, MD, PhD (1) · Anoop Misra, MD (1) · Arshiya Baig, MD (1) · Arun K Sigurdardottir, PhD (1) · Choon Ok Kim, M.D., Ph.D. (1) · Dmitry Napalkov (1) · Hai Li, professor (1) · Hongzhong Liu (1) · Jassim Al-Suwaidi, MD (1) · Joel M Neutel, M. D. (1) · John Flood (1) · Kazuomi Kario, MD (1)
PMID 38456558, PMID 39054871, PMID 14578255, PMID 16644654, PMID 17315136, PMID 19490820, PMID 23668478, PMID 24631482, PMID 25425451, PMID 25739882, PMID 26652763, PMID 26972954, PMID 27679584, PMID 27814267, PMID 28096223, PMID 28428225, PMID 28615237, PMID 28775741, PMID 29227578, PMID 30149145, PMID 30586745, PMID 31897475, PMID 32198674, PMID 36756676, PMID 37102010, PMID 38837240, PMID 39174014, PMID 39487428, PMID 39709140, PMID 40175670, PMID 40975112, PMID 41252113, PMID 42150836
2025 (1), P50MD017349 (1), R01DK135948 (1)